S&P 500   3,855.36
DOW   30,960.00
QQQ   328.11
S&P 500   3,855.36
DOW   30,960.00
QQQ   328.11
S&P 500   3,855.36
DOW   30,960.00
QQQ   328.11
S&P 500   3,855.36
DOW   30,960.00
QQQ   328.11
Log in
NASDAQ:PRTK

Paratek Pharmaceuticals Stock Forecast, Price & News

$6.76
+0.10 (+1.50 %)
(As of 01/25/2021 12:00 AM ET)
Add
Compare
Today's Range
$6.51
Now: $6.76
$6.80
50-Day Range
$6.14
MA: $6.56
$7.14
52-Week Range
$2.50
Now: $6.76
$7.27
Volume252,329 shs
Average Volume346,023 shs
Market Capitalization$308.53 million
P/E RatioN/A
Dividend YieldN/A
Beta1.62
Paratek Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization life-saving therapies for life-threatening diseases or other public health threats for civilian, government, and military use. Its lead product candidates include NUZYRA, a once-daily oral and intravenous broad-spectrum antibiotic for the treatment of adult patients with community-acquired bacterial pneumonia and acute bacterial skin and skin structure infections caused by susceptible pathogens; and SEYSARA, a tetracycline designed for the treatment of moderate to severe acne vulgaris. The company has license and collaboration agreements with Zai Lab (Shanghai) Co., Ltd. and Allergan plc; license agreement with Tufts University to develop and commercialize products for the treatment or prevention of bacterial or microbial diseases, or medical conditions; and cooperative research and development agreement with the U.S. Army Medical Research Institute of Infectious Diseases to study omadacycline against pathogenic agents causing infectious diseases. Paratek Pharmaceuticals, Inc. was founded in 1996 and is headquartered in Boston, Massachusetts.
Paratek Pharmaceuticals logo

MarketRank

Overall MarketRank

1.51 out of 5 stars

Medical Sector

410th out of 1,922 stocks

Pharmaceutical Preparations Industry

213th out of 771 stocks

Analyst Opinion: 3.5Community Rank: 2.6Dividend Strength: 0.0Insider Behavior: 0.8Valuation: 0.6 5 -4 -3 -2 -1 -

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryPharmaceuticals
SectorMedical
Current SymbolNASDAQ:PRTK
Previous SymbolNASDAQ:TSPT
CUSIP89354M10
Phone617-807-6600
Employees101
Year FoundedN/A

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$16.54 million
Book Value($1.19) per share

Profitability

Net Income$-128,790,000.00
Net Margins-248.03%

Miscellaneous

Market Cap$308.53 million
Next Earnings Date2/23/2021 (Estimated)
OptionableOptionable
$6.76
+0.10 (+1.50 %)
(As of 01/25/2021 12:00 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive PRTK News and Ratings via Email

Sign-up to receive the latest news and ratings for PRTK and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Paratek Pharmaceuticals (NASDAQ:PRTK) Frequently Asked Questions

How has Paratek Pharmaceuticals' stock been impacted by Coronavirus?

Paratek Pharmaceuticals' stock was trading at $3.89 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization (WHO). Since then, PRTK stock has increased by 73.8% and is now trading at $6.76.
View which stocks have been most impacted by COVID-19
.

Is Paratek Pharmaceuticals a buy right now?

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Paratek Pharmaceuticals in the last twelve months. There are currently 3 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" Paratek Pharmaceuticals stock.
View analyst ratings for Paratek Pharmaceuticals
or view MarketBeat's top 5 stock picks.

What stocks does MarketBeat like better than Paratek Pharmaceuticals?

Wall Street analysts have given Paratek Pharmaceuticals a "Buy" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Paratek Pharmaceuticals wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

When is Paratek Pharmaceuticals' next earnings date?

Paratek Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Tuesday, February 23rd 2021.
View our earnings forecast for Paratek Pharmaceuticals
.

How were Paratek Pharmaceuticals' earnings last quarter?

Paratek Pharmaceuticals, Inc. (NASDAQ:PRTK) issued its quarterly earnings data on Thursday, November, 5th. The specialty pharmaceutical company reported ($0.46) earnings per share for the quarter, beating the Zacks' consensus estimate of ($0.61) by $0.15. The specialty pharmaceutical company had revenue of $13.66 million for the quarter, compared to analyst estimates of $11.89 million.
View Paratek Pharmaceuticals' earnings history
.

What guidance has Paratek Pharmaceuticals issued on next quarter's earnings?

Paratek Pharmaceuticals issued an update on its FY 2020 After-Hours earnings guidance on Thursday, November, 5th. The company provided EPS guidance of for the period. The company issued revenue guidance of $83-83 million, compared to the consensus revenue estimate of $82.05 million.

What price target have analysts set for PRTK?

3 brokerages have issued 1-year price objectives for Paratek Pharmaceuticals' shares. Their forecasts range from $14.00 to $22.00. On average, they anticipate Paratek Pharmaceuticals' share price to reach $18.00 in the next year. This suggests a possible upside of 166.3% from the stock's current price.
View analysts' price targets for Paratek Pharmaceuticals
or view Wall Street analyst' top-rated stocks.

Who are some of Paratek Pharmaceuticals' key competitors?

What other stocks do shareholders of Paratek Pharmaceuticals own?

Who are Paratek Pharmaceuticals' key executives?

Paratek Pharmaceuticals' management team includes the following people:
  • Mr. Michael F. Bigham C.P.A., M.B.A., CPA, MBA, Exec. Chairman (Age 62, Pay $881.68k)
  • Dr. Evan Loh, CEO & Director (Age 61, Pay $906.9k)
  • Mr. Adam Woodrow, Pres & Chief Commercial Officer (Age 53, Pay $672.21k)
  • Mr. William M. Haskel, Sr. VP, Gen. Counsel, Corp. Sec. & Chief Compliance Officer (Age 58, Pay $586k)
  • Ms. Sarah Higgins, VP, Controller and Interim Principal Financial & Accounting Officer (Age 45)
  • Mr. Jason Burdette, Sr. VP of Technical Operations
  • Mr. Ben Strain, VP of Investor Relations & Corp. Communications and Chief of Staff to the CEO
  • Ms. Christine R. Coyne M.B.A., VP of Marketing
  • Ms. Karen McGrath, Sr. VP of HR
  • Mr. Randall B. Brenner, Chief Devel. & Regulatory Officer (Age 47)

What is Paratek Pharmaceuticals' stock symbol?

Paratek Pharmaceuticals trades on the NASDAQ under the ticker symbol "PRTK."

How do I buy shares of Paratek Pharmaceuticals?

Shares of PRTK can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Paratek Pharmaceuticals' stock price today?

One share of PRTK stock can currently be purchased for approximately $6.76.

How big of a company is Paratek Pharmaceuticals?

Paratek Pharmaceuticals has a market capitalization of $308.53 million and generates $16.54 million in revenue each year. The specialty pharmaceutical company earns $-128,790,000.00 in net income (profit) each year or ($3.93) on an earnings per share basis. Paratek Pharmaceuticals employs 101 workers across the globe.

What is Paratek Pharmaceuticals' official website?

The official website for Paratek Pharmaceuticals is www.paratekpharma.com.

How can I contact Paratek Pharmaceuticals?

Paratek Pharmaceuticals' mailing address is 75 PARK PLAZA, BOSTON MA, 02116. The specialty pharmaceutical company can be reached via phone at 617-807-6600 or via email at [email protected]

This page was last updated on 1/26/2021 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.